MARKET

FULC

FULC

Fulcrum Therapeutics
NASDAQ
3.020
+0.050
+1.68%
After Hours: 3.020 0 0.00% 16:02 03/20 EDT
OPEN
2.950
PREV CLOSE
2.970
HIGH
3.100
LOW
2.950
VOLUME
295.76K
TURNOVER
--
52 WEEK HIGH
11.48
52 WEEK LOW
2.780
MARKET CAP
163.02M
P/E (TTM)
-19.2479
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FULC last week (0310-0314)?
Weekly Report · 4d ago
Weekly Report: what happened at FULC last week (0303-0307)?
Weekly Report · 03/10 11:56
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
Benzinga · 03/05 18:21
Fulcrum Therapeutics, MyoKardia end agreement on cardiomyopathy treatments
Seeking Alpha · 03/05 17:39
Fulcrum Therapeutics Has Received Written Notice From Bristol Myers Squibb-Acquired MyoKardia To End Their Collaboration And License Agreement, Originally Signed On July 20, 2020, The Termination Will Officially Take Effect On June 26, 2025-8K
Benzinga · 03/05 11:46
Fulcrum Therapeutics Faces Termination of Key Agreement
TipRanks · 03/04 22:27
FULCRUM THERAPEUTICS INC - TERMINATION EFFECTIVE JUNE 26, 2025
Reuters · 03/04 22:03
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Barchart · 03/04 15:05
More
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Webull offers Fulcrum Therapeutics Inc stock information, including NASDAQ: FULC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FULC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FULC stock methods without spending real money on the virtual paper trading platform.